That's exactly right. If lenz is being used as the game-changing therapeutic that dramatically enhanced Gracell's CAR-T (think 24 hour cycle to customize patient treatment compound, versus 6 weeks+), then that should, at a minimum, represent a licensing fee source of revenue for Humanigen.
Market Data 
Markets 
AI
